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Posttraumatic stress disorder (PTSD) is a trauma and stressor related disorder that
may develop after exposure to an event that involved the actual or possible threat
of death, violence or serious injury. Its molecular underpinning is still not clear.
Brain-derived neurotrophic factor (BDNF) modulates neuronal processes such as the
response to stress, but also weight control, energy and glucose homeostasis. Plasma
BDNF levels and a functional BDNF Val66Met (rs6265) polymorphism were reported
to be associated with PTSD, as well as with increased body mass index (BMI) and
dyslipidaemia in healthy subjects and patients with cardio-metabolic diseases, but these
results are controversial. The other frequently studied BDNF polymorphism, C270T
(rs56164415), has been associated with the development of different neuropsychiatric
symptoms/disorders. As far as we are aware, there are no data on the association
of BDNF Val66Met and C270T polymorphisms with metabolic indices in PTSD.
Due to high rates of obesity and dyslipidaemia in PTSD, the aim of this study
was to elucidate the association of BDNF Val66Met and C270T polymorphisms
with BMI and lipid levels in veterans with PTSD. We hypothesized that BDNF
variants contribute to susceptibility to metabolic disturbances in PTSD. The study
included 333 Caucasian males with combat related PTSD, diagnosed according to
DSM-5 criteria. Genotyping of the BDNF Val66Met and C270T polymorphisms was
performed using the real-time PCR method. Results were analyzed using hierarchical
multiple linear regression and the Mann–Whitney test, with p-value corrected to
0.005. The results showed that BDNF Val66Met and BDNF C270T polymorphisms
were not significantly associated with BMI, total cholesterol, LDL-cholesterol,
HDL-cholesterol or triglycerides. Although the BDNF C270T polymorphism was
nominally associated only with HDL-cholesterol in veterans with PTSD, this significance
disappeared after controlling for the effect of age. Namely, slightly higher plasma
HDL values in T allele carriers, compared to CC homozygotes, were associated
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with differences in age. Our results, controlled for the critical covariates, revealed that
BDNF Val66Met and C270T were not significantly associated with metabolic indices in
veterans with PTSD and that these genetic variants do not contribute to susceptibility to
metabolic disturbances in PTSD.
Keywords: BDNF, Val66Met, C270T, BMI, plasma lipid levels, metabolic indices, PTSD
INTRODUCTION
Posttraumatic Stress Disorder
Posttraumatic stress disorder (PTSD) is a trauma- and stressor-
related disorder (1) that develops in some, but not all individuals
exposed to death, threatened death, actual or threatened serious
injury, or actual or threatened sexual violence. Its molecular
underpinning is still not clear. Various potential stressful
events or traumas happen to people during their lifetime,
but different populations vary in their exposure to traumatic
events (2, 3). PTSD commonly co-occurs with different somatic
disorders (4), such as cardiovascular, metabolic, dermatological,
musculoskeletal, and pulmonary diseases (5).
Metabolic Disturbances in PTSD
Metabolic complications and components of the metabolic
syndrome are associated with increased body mass index (BMI)
values or weight gain, and with other clusters of physiological,
biochemical, clinical, and metabolic factors that strongly increase
the risk of type 2 diabetes and different cardiovascular diseases
(6). These metabolic abnormalities include central obesity
measured as waist circumference, dyslipidaemia (reduced HDL
levels and increased triglyceride levels), high blood pressure,
insulin resistance, as well as raised fasting plasma glucose.
People with a sedentary life style, who do not exercise, consume
a high fat diet and develop these metabolic abnormalities,
have increased risk for cardiovascular and metabolic
disorders (6).
Metabolic syndrome is frequent in PTSD (7–14). Metabolic
complications include insulin resistance (15), higher mean
triglycerides, higher blood pressure and fasting glucose levels,
and lower HDL values in individuals with PTSD than in subjects
from the general population (8). Young US veterans with PTSD
had BMI values in the overweight range, higher than controls
(15). Similarly, Croatian veterans with combat related PTSD
had more frequently comorbid cardiometabolic disorders than
control subjects (5), and this population had a high prevalence of
obesity (16). Therefore, there is an urgent need for establishing
the potential biomarkers of metabolic disturbances in
PTSD (17).
Brain-Derived Neurotrophic Factor
The most abundant neurotrophin in the central nervous
system is brain-derived neurotrophic factor (BDNF) and it
modulates neuronal differentiation, synapse formation, survival,
support and function of neurons, brain neurotransmission,
proliferation, long-term potentiation, and synaptic growth
in the central nervous system (18). Due to its localization
and expression in the limbic system, brain regions that
are involved in the regulation of fear and stress responses,
and its modulatory role in dopaminergic, serotonergic and
glutamatergic synthesis, metabolism, neuronal activity and
release (18, 19), it is not surprising that BDNF is involved in the
development of different neuropsychiatric disorders, including
PTSD (19–21).
BDNF Genetic Variants
In humans, BDNF is encoded by the BDNF gene which extends
over 70 kb, located on chromosome 11, region p13–14 (22).
There are hundreds of polymorphisms in the BDNF gene,
however, the most frequently studied functional polymorphisms
include the Val66Met single-nucleotide polymorphism (rs6265)
in the coding exon (23), and the C270T single-nucleotide
polymorphism (rs56164415), in the 5′-untranslated region
(UTR) of the BDNF gene (24). The A (Met) allele, compared
to the G (Val) allele, of the BDNF Val66Met is associated
with disrupted cellular processing, trafficking and intracellular
packaging of the pro-BDNF and reduced activity-dependent
secretion of the mature BDNF (23, 25). The other polymorphism,
BDNF C270T, in the BDNF 5’-non-coding region (26), may
affect BDNF expression (27) and might lead to regionally specific
quantitative BDNF disbalance in the brain (24). Consequently,
both BDNF polymorphisms, BDNF Val66Met (19, 28) and
BDNF C270T (24, 29) have been associated with different
neuropsychiatric disorders.
BDNF and PTSD
In patients with PTSD, inconsistent findings were reported
regarding peripheral BDNF levels: blood levels were reported
to be decreased (30), unchanged (31, 32), or increased (15,
33, 34). However, a meta-analysis did not confirm a significant
association between BDNF levels and PTSD (35), which is in
line with no significant relationship between cerebrospinal fluid
BDNF levels and PTSD (36). There are conflicting findings
on the relationship between BDNF genetic variants and PTSD
(21, 37–40). The association between BDNF Val66Met and PTSD
was confirmed in only one study (40), while other studies
failed to detect a significant association (41–45). The association
between PTSD and the other C270T polymorphism in the BDNF
gene was investigated in two individual case-control studies,
producing opposite results: positive (46) as well as no (45)
association.
BDNF and Metabolic Complications
The localization of BDNF in the hippocampus and the
hypothalamus explains its moderating effects on energy
metabolism, homeostasis, metabolic regulation (47, 48), weight
control, fasting and feeding (49, 50). BDNF is located also in
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lungs, heart, spleen, gastrointestinal tract and liver, and it is
involved in the development of cardiovascular and metabolic
disorders, metabolic syndrome (51), and body weight gain
(52, 53). In the blood, BDNF is stored mainly in platelets and
released into plasma (54), but it is also synthesized and released
from different cell types including cells from the cardiovascular
system (55, 56), pancreatic beta cells, as well as cells from adipose
tissue (57). BDNF exhibits an anorexigenic effect and suppresses
food intake (48). A sedentary life style, overweight, obesity
and lack of exercise are related to reduced BDNF signaling
and increased activity of the sympathetic nervous system,
decreased activity of the parasympathetic outflow, increased
heart rate, blood pressure, elevated inflammation, and reduced
gut motility (49).
There are conflicting data regarding an association of plasma
or serum BDNF levels and metabolic indices. Reduced BDNF
levels were detected in patients with type 2 diabetes (58),
metabolic or coronary syndromes (57, 59, 60), non-obese and
non-diabetic subjects with acute coronary syndrome (60), and
in patients with angina pectoris (61). Increased BDNF levels
were found in a population based study showing a positive
association with increased risk for obesity, metabolic syndrome
and coronary disease (51, 62). In contrast, in another study,
subjects with or without metabolic syndrome had similar serum
BDNF levels (63). A recent meta-analysis found lower BDNF
levels associated with the presence of metabolic syndrome in
healthy adult subjects (64). On the other hand, a longitudinal
study including a large community-based cohort (65) detected
higher serum BDNF levels significantly associated with lower
risk of cardiovascular diseases and mortality, independent of
markers of low-grade inflammation, BMI, physical activity, and
depression.
BDNF gene variants were studied as risk factors for metabolic
complications, such as BMI, dyslipidaemia, obesity, insulin
resistance (66–68) and eating disorders (19). The A allele of
the BDNF Val66Met polymorphism has been associated with
higher BMI in adult women (69) and in young preschool children
(70), but not in older healthy individuals (71). When these adult
healthy groups were enlarged, a significant association was found
between BMI categories and BDNF Val66Met (52, 72), since the A
allele wasmore frequently found in the group with normal weight
(52, 72–74). In conformation, obese subjects more frequently had
the G allele of the BDNF Val66Met (73, 75). As far as we are
aware, the reports on the association between the BDNF C270T
polymorphism and BMI or plasma lipid levels in humans have
not been studied.
In addition, to the best of our knowledge, there are no
data on the association of BDNF Val66Met and BDNF C270T
polymorphisms with metabolic indices in PTSD. Due to the high
rates of both obesity and dyslipidaemia in PTSD, the aim of
this study was to elucidate the association of BDNF Val66Met
and BDNF C270T polymorphisms with BMI and lipid levels
in veterans with PTSD. We hypothesized that BDNF variants
might contribute to susceptibility to metabolic disturbances in
PTSD and that these BDNF metabolic-risk variants might be
more frequently present in patients with PTSD in comparison to
healthy subjects or other diagnostic categories.
METHODS
Participants
The study included 333 male veterans with combat related
PTSD, with median Clinician Administered PTSD Scale (CAPS)
scores of 86 (range 68–102). They were all unrelated Caucasian
subjects of Croatian origin. The diagnosis of current and
chronic PTSD was done using SCID based on DSM-5 criteria
(1). Participants were sampled consecutively in the University
Psychiatric Hospital Vrapce, Zagreb, from September 2015 to
June 2017. They were exposed to similar potentially traumatic
events during the Homeland war in Croatia. Inclusion criteria
were in- and out-patients aged 38–77 years. Exclusion criteria
were: drug abuse, alcohol dependence or pathophysiological
changes in the liver, such as fibrosis, sclerosis, cirrhosis
and malignant liver disease [alcoholic liver cirrhosis (K70.3),
alcoholic liver fibrosis and sclerosis (K70.2) and hepatocellular
carcinoma (C22.0), according to ICD-10], schizophrenia, bipolar
disorder, adult ADHD, Alzheimer’s disease (according to DSM-
5 criteria), current or recent (previous 3 months) use of lipid-
lowering agents, antihypertensive and antidiabetic medication.
The study was approved by the Ethics Committee of the
University Psychiatric Hospital Vrapce, Zagreb, Croatia, and was
carried out in accordance with the Helsinki declaration (1975), as
revised in 1983. All patients have signed informed consent prior
to study procedures.
Anthropological Measures
Height of subjects wearing no shoes wasmeasured with ameter to
the nearest 0.5 cm; whereas body weight of subjects wasmeasured
with a digital scale to the nearest 0.1 kg. BMI was calculated as
ratio of weight (kg) over height (m2).
Measurements of the Metabolic Indices
Blood samples were collected between 7:30 a.m. and 8:00 a.m.
after overnight fasting. Total cholesterol (normal values <5
mmol/l) was determined with cholesterol oxidase-phenol
aminophenazone method and the absorbance read on a Siemens
Dimension Xpand analyser. Triglycerides (normal values <1.7
mmol/l), LDL (normal values <3 mmol/l), and HDL (normal
values >1.2 mmol/L) were determined using the enzymatic-
colorimetric assay and were analyzed with Siemens Dimension
Xpand analyser.
Genotyping
Genomic DNA was isolated from peripheral blood using a
salting out method (76). BDNF Val66Met (rs6265) and C270T
(rs56164415) were determined with TaqMan R© Genotyping
Assays (Applied Biosystems, Foster City, CA, USA) following
the manufacturer’s protocol on an Applied Biosystems R© 7300
Real-Time PCR System apparatus. The 10 µL reaction volume
contained around 20 ng of DNA. Assay IDs were C_11592758_10
for rs6265 and C_89097201_10 for rs56164415. Around 10% of
randomly selected samples were genotyped again as a quality
control for genotyping assays.
Minor allele frequency (MAF) for BDNF Val66Met in our
sample was 19% (A allele), which is in accordance with the
MAF of 20% (A allele) in the European population (77). In our
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European sample, MAF for BDNF C270T was 17% (T allele),
while 1000 Genomes reports much smaller frequency of T allele
(6%) in this population.
Since there were only 6 AA genotype carriers (of the BDNF
Val66Met) and 3 TT genotype carriers (of the BDNF C270T) in
the whole sample, we assessed only the dominant model for the
BDNF Val66Met: A carriers (AA + AG) vs. GG homozygous
genotype, and the dominant model for the BDNF C270T: T
carriers (TT+ TC) vs. CC homozygous genotype (78, 79).
Statistical Analysis
All data regarding lipid levels, BMI and age failed to reach
normal distribution (Kolmogorov-Smirnov test). The data were
expressed as median, 25th (Q1) and 75th (Q3) percentile after
excluding outliers. Outliers were determined as values that lie
below Q1–1.5 interquartile range (IQR) or above Q3+1.5 IQR.
Hierarchical multiple linear regression was used to determine
possible effect of age, smoking, BMI, BDNF Val66Met, and
BDNF C270T on each metabolic parameter after excluding
outliers. The data were evaluated with the non-parametricMann-
Whitney test for each metabolic parameter using Sigma Stat
3.5 (Jandell Scientific Corp. San Raphael, California, USA). For
determination of the linkage disequilibrium (LD) between BDNF
Val66Met and C270T loci, we used Haploview software v. 4.2
(80). Loci are considered to be in high LD if the D’ coefficient
is >0.80 and logarithm of odds (LOD) ≥ 2 (80, 81). In our study
these two loci were not in high LD since the D′ coefficient was
<0.80 (D′ = 0.36; LOD = 0.32). Therefore, we did not perform
haplotype analysis. Due to multiple (N = 10) comparisons
(testing the association of 2 single nucleotide polymorphisms
(SNPs) with 5 metabolic indices=10), a Bonferroni correction
was performed and p-value was set to p= 0.005. Before the study
G∗Power 3 Software (82) was used to determine the required
sample size and actual statistical power. For hierarchical multiple
linear regression, with p = 0.005; medium effect size = 0.25;
and power (1 – β) = 0.800; number of predictors = 5; the
required sample size was 142. For the Mann–Whitney test, with
p= 0.005; medium effect size= 0.15; and power (1 – β)= 0.800;
the required sample size was 217. Since the study included 333
participants in the beginning, and 294–311 participants after the
removal of outliers, it had adequate sample size and statistical
power to detect significant differences among the groups.
RESULTS
Clinical Data
Demographic and clinical data, including age, levels of total, HDL
and LDL cholesterol, triglyceride levels, and BMI, of veterans
with PTSD are presented in Table 1. Initially, the study enrolled
333 subjects. However, after removal of the outliers for each
metabolic parameter (values that were lower than Q1–1.5 IQR
or higher Q3+1.5 IQR in our sample), there were N = 294
participants for HDL (removed HDL values ≤0.5 and HDL ≥
2.0), N = 316 for BMI (removed BMI values ≤19); N = 315
for cholesterol (removed cholesterol values ≥8.4), N = 311 for
LDL (removed LDL values≥5.7 and LDL≤0.2) and N = 303 for
triglycerides (removed triglyceride values ≥3.8), respectively.
TABLE 1 | Demographic and clinical data of veterans with PTSD.
N Median (25th; 75th) Min–Max
Age (years) 333 56 (51; 63) 38–77
TC (mmol/L) 315 5.20 (4.50; 6.00) 2.90–8.10
HDL (mmol/L) 294 1.20 (1.10; 1.40) 0.80–1.80
LDL (mmol/L) 311 2.80 (2.40; 3.60) 0.90–5.60
TG (mmol/L) 303 1.60 (1.30; 2.20) 0.60–3.70
BMI (kg/m2) 316 28.03 (25.85; 30.45) 20.32–35.92
Results are presented as median and 25th (Q1) and 75th (Q3) percentiles. N is
number of subjects after removing outliers. PTSD, posttraumatic stress disorder; TC,
total cholesterol; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein
cholesterol; TG, triglycerides; BMI, body mass index.
The Effect of Age, Smoking, BMI, and
BDNF Polymorphisms on Metabolic
Parameters
Hierarchical multiple linear regression was performed in order
to assess the influence of various independent variables, such
as age, smoking, BMI, and BDNF Val66Met and BDNF
C270T on different metabolic parameters (dependent variables)
(Table 2). It was designed in the following way: for all
metabolic indices, except BMI, the first step included age,
BMI, and smoking status as dependent variables, and the
second step BDNF Val66Met genotype (dominant model)
and BDNF C2790T genotype (dominant model). For BMI,
age, and smoking were entered as dependent variables in
the first step, while both genotypes were added in the
second one. Hierarchical multiple regression revealed age as
the only significant (p < 0.001) variable influencing HDL
and triglycerides, while other variables were not significantly
associated with metabolic indices due to Bonferroni corrected
significance (p= 0.005).
BDNF Val66Met and BDNF C270T
Polymorphisms and Metabolic Indices
Table 3 shows that metabolic parameters did not differ
significantly between individuals with PTSD subdivided into
A carriers (AA+AG) vs. homozygous GG genotype carriers
of BDNF Val66Met, as well as between T carriers (TT+CT)
vs. CC genotype carriers of the BDNF C270T. Namely, no
significant differences between A carriers and GG homozygotes
of the BDNF Val66Met polymorphism, were detected in the
BMI values (p = 0.979), plasma concentrations of total
(p = 0.933), HDL (p = 0.829), and LDL (p=0.146) cholesterol,
as well as triglycerides (p = 0.409). In the case of the
BDNF C270T polymorphism, similar results were observed. The
Mann Whitney test revealed that BMI (p = 0.822), plasma
concentrations of total (p = 0.738) and LDL (p = 0.290)
cholesterol, as well as triglyceride (p = 0.092) levels were
similar in T carriers and CC homozygotes. However, HDL
levels differed nominally (p = 0.006) between T carriers and
CC homozygotes of the BDNF C270T polymorphism. Since
this association was not confirmed using hierarchical multiple
linear regression, the observed difference in HDL levels was
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TABLE 2 | Hierarchical multiple linear regression showing variables influencing different metabolic parameters.
TC HDL LDL TG BMI
Step 1 Model
summary
adjR2 = −0.006;
1R2 = 0.005;
F = 0.449;
p = 0.718
adjR2 = 0.065;
1R2 = 0.076;
F = 7.355;
p < 0.001;
adjR2 = −0.004;
1R2 = 0.006;
F = 0.621;
p = 0.602;
adjR2 = 0.042;
1R2 = 0.052;
F = 5.057;
p = 0.002;
adjR2 = −0.003;
1R2 = 0.004;
F = 0.577; p = 0.652;
Age β = −0.051;
p = 0.387
β = −0.246;
p < 0.001
β = 0.039;
p = 0.508
β = 3.406;
p = 0.001
β = 0.015; p = 0.804
BMI β = 0.034;
p = 0.564
β = 0.129;
p = 0.029
β = −0.070;
p = 0.237
β = −0.012;
p = 0.835
–
Smoking β = 0.032;
p = 0.583
β = 0.008;
p = 0.896
β = −0.015;
p = 0.798
β = 0.116;
p = 0.050
β = −0.061;
p = 0.299
Step 2 Model
summary
adjR2 = −0.006;
1R2 = 0.006;
F = 0.637;
p = 0.672;
adjR2 = 0.065;
1R2 = 0.007;
F = 4.820;
p < 0.001;
adjR2 = −0.008;
1R2 = 0.003;
F = 0.537;
p = 0.746;
adjR2 = 0.040;
1R2 = 0.005;
F = 3.337;
p = 0.006;
adjR2 = −0.010;
1R2 = 0.000;
F = 0.300; p = 0.878;
Age β = −0.023;
p = 0.714
β = −0.216;
p = 0.001
β = 0.037;
p = 0.552
β = 2.922;
p = 0.004
β = 0.014; p = 0.820
BMI β = 0.033;
p = 0.573
β = 0.128;
p = 0.030
β = −0.070;
p = 0.209
β = −0.012;
p = 0.842
–
Smoking b = 0.035;
p = 0.557
β = 0.009;
p = 0.877
β = −0.015;
p = 0.806
β = 0.113;
p = 0.055
β = −0.061;
p = 0.302
BDNF
Val66Met
β = −0.020;
p = 0.735
β = 0.007;
p = 0.908
β = −0.050;
p = 0.398
β = 0.062;
p = 0.298
β = −0.013;
p = 0.828
BDNF C270T β = −0.084;
p = 0.180
β = −0.088;
p = 0.162
β = 0.016;
p = 0.803
β = 0.048;
p = 0.434
b = −0.004;
p = 0.953
A carriers (AA + AG) combined genotypes of the BDNF Val66Met; T carriers (TT + TC) combined genotypes of the BDNF C270T; BDNF, brain derived neurotrophic factor; BMI, body
mass index; TC, total cholesterol; HDL: high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; TG, triglycerides.
presumably associated with the age differences between these
groups.
Therefore, as age was a significant (p < 0.001) variable that
affects HDL and triglycerides in the regression model, and HDL
levels were nominally (p = 0.006) different between T carriers
and CC homozygotes, to further evaluate this age-related, but
also BDNF C270T -related influence, patients were additionally
subdivided into 3 age groups. Since the age range of the patients
was 38–77, we subdivided participants into approximately 13-
year age groups, i.e., into individuals between the ages of 38
and 51 (N = 76 for HDL, and N = 74 for triglycerides after
removing outliers), ages 52–65 (N = 162 for HDL, N = 171 for
triglycerides), and ages 66–77 (N = 56 for HDL and N = 58
for triglycerides). The Mann-Whitney test demonstrated no
significant (p > 0.005) differences between BDNF Val66Met A
vs. GG genotype carriers, and between BDNF C270T T vs. CC
genotype carriers in HDL and triglyceride levels (Table 4) in each
age group. These results revealed that these two polymorphisms
were not significantly associated with HDL and triglyceride levels
in any of the age groups. Nevertheless, median HDL values
(Table 4) showed a decline (as evidenced by the multiple linear
regression analysis: β=−0.243) with increased age in both T and
CC genotype carriers.
DISCUSSION
The results of this study revealed that in a homogeneous
sample of middle-aged Caucasian (Croatian origin) veterans with
combat related PTSD: (1) BDNF Val66Met and BDNF C270T
polymorphisms were not significantly associated with BMI or
plasma lipid levels; (2) the presence of one or two T alleles of
BDNF C270T polymorphism was related to slightly (nominally)
higher HDL cholesterol values; but this association disappeared
after controlling for the influence of age.
In the present study, veterans had chronic and current PTSD,
and moderate PTSD symptoms, as revealed by their mean
CAPS scores of 86 (range 68–102) (83). Their lipid levels were
either slightly higher (total cholesterol and triglycerides) or
within the normal laboratory range (i.e., for HDL and LDL
cholesterol levels). Data from the literature regarding lipid levels
in PTSD are inconsistent (84). Similar HDL and LDL cholesterol
levels were found in different groups of Caucasian veterans
with PTSD of the same origin (85), or in Japanese civilians
with PTSD, who were victims of sarin poisoning (86). Further,
HDL levels did not differ between civilian participants with
and without PTSD (87, 88). Similarly, PTSD was associated
with unchanged LDL cholesterol levels (89, 90). Other studies
found dyslipidaemia, i.e., increased cholesterol, triglyceride, and
LDL cholesterol levels in PTSD (88, 91–93). In contrast to our
data, some studies have detected lower HDL cholesterol levels
in PTSD (89, 90, 94), or similar triglyceride levels in large
groups of community-living adults with or without PTSD (87).
Further, cholesterol, LDL cholesterol and triglyceride levels did
not differ between participants with PTSD compared to non-
PTSD individuals (94). Dyslipidaemia and increased BMI are
risk factors for various cardiovascular diseases and myocardial
Frontiers in Psychiatry | www.frontiersin.org 5 November 2018 | Volume 9 | Article 637
Tudor et al. BDNF and Lipids in PTSD
TABLE 3 | The metabolic parameters of veterans with PTSD subdivided according to the BDNF Val66Met and BDNF C270T genetic variants.
SNP BDNF Val66Met BDNF C270T
Genotype A carriers GG carriers T carriers CC carriers
BMI
(kg/m2)
Median 27.75 27.91 27.77 28.06
Percentile
25th; 75th
26.26; 30.11 25.69; 30.47 25.86; 30.47 26.03; 30.45
Min; Max 20.32; 35.92 20.76; 35.71 20.76; 33.91 21.26; 35.92
Statistics U = 10581.00; p = 0.979 U = 10743.50; p = 0.822
TC
(mmol/L)
Median 5.20 5.20 5.20 4.90
Percentile
5th; 75th
4.50; 5.70 4.50; 6.10 4.50; 6.10 4.50; 6.00
Min; Max 2.90; 8.10 2.90; 7.90 3.00; 8.10 2.90; 7.90
Statistics U = 10485.00; p = 0.933 U = 10555.00; p = 0.738
HDL
(mmol/L)
Median 1.20 1.20 1.20 1.20
Percentile
25th; 75th
1.10; 1.40 1.10; 1.40 1.10; 1.50 1.10; 1.30
Min; Max 0.80; 1.80 0.80; 1.80 0.80; 1.80 0.80; 1.80
Statistics U = 9065.50; p = 0.829 U = 7561.50; p = 0.006
LDL
(mmol/L)
Median 3.00 2.80 2.80 2.90
Percentile
25th; 75th
2.40; 3.60 2.30; 3.50 2.20; 3.60 2.40; 3.60
Min; Max 0.90; 5.40 0.90; 5.60 0.90; 5.60 0.90; 5.40
Statistics U = 9157.00; p = 0.146 U = 9658.00; p = 0.290
TG
(mmol/L)
Median 1.60 1.60 1.55 1.60
Percentile
25th; 75th
1.30; 2.10 1.30; 2.20 1.20; 2.10 1.30; 2.30
Min; Max 0.60; 3.70 0.60; 3.70 0.60; 3.70 0.60; 3.70
Statistics U = 9165.50; p = 0.409 U = 8637.00; p = 0.092
Results are presented as median and 25th (Q1) and 75th (Q3) percentiles after excluding outliers. A carriers (AA + AG) of the BDNF Val66Met; GG (GG homozygous genotype) carriers
of the BDNF Val66Met; T carriers (TT + TC) of the BDNF C270T; CC carriers (CC homozygous genotype) of the BDNF C270T; BDNF: brain derived neurotrophic factor; BMI, Body
mass index; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; PTSD, posttraumatic stress disorder; TC, total cholesterol; TG, triglycerides.
infarction in all subjects (6), especially individuals with PTSD
(4, 8, 10, 13). Therefore, careful monitoring of these patients is
warranted to prevent development of cardiometabolic disorders.
The current investigation included patients with PTSD without
cardiovascular diseases and the exclusion criteria included taking
cardiovascular drugs or statins, but their mean BMI values
of almost 28 suggest that the majority of participants were
overweight. This is in line with data obtained with the different
groups of Croatian veterans with PTSD (16) but also with data
from a Croatian population sample (16), and with findings from
young military US veterans with PTSD, who were all overweight
(15). All these findings suggest that overweight, obesity and
dyslipidaemia are becoming health risks in PTSD, but also global
health problems in the general population. Various risk factors
such as different diagnoses and sizes of the groups, civilian or
military individuals, diet, food, sedentary life style and physical
activity, age, exercise, alcohol dependence, and smoking might
affect BMI and lipid levels. As this study did not intend to
compare BMI and lipid levels between individuals with PTSD
and control subjects, we may conclude that our results on the
lipid levels and BMI are in line with most of the cited data.
There was one study showing positive association (40)
and others reporting no associations (41–45) between BDNF
Val66Met and PTSD. In our previous study that included
different groups of war veterans (42), the frequency of the
BDNF Val66Met genotypes did not differ between veterans
with or without PTSD. Therefore, the present study with other
groups of veterans with PTSD did not evaluate this possible
association and did not include control subjects. The explanation
for these inconsistent findings might be sought in the frequency
of trauma exposure, traumatic load, early traumatic experience
and stressful life events, age, and other study conditions among
the participants (21).
We did not confirm our hypothesis that BDNF variants
contributed to susceptibility to metabolic disturbances in
PTSD. In our study BDNF Val66Met polymorphism was not
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TABLE 4 | The HDL and TG values in different age groups of veterans with PTSD subdivided according to the BDNF Val66Met and BDNF C270T genetic variants.
Age group 38–51 years 52–65 years 66–77 years
BDNF
Val66Met
Genotype A
carriers
(N = 32)
GG
carriers
(N = 44)
A
carriers
(N = 56)
GG
carriers
(N = 106)
A
carriers
(N = 15)
GG
carriers
(N = 41)
HDL
(mmol/L)
Median 1.30 1.30 1.20 1.20 1.20 1.10
Percentile 25th;
75th
1.10; 1.50 1.10; 1.50 1.00; 1.30 1.10; 1.30 1.10; 1.20 1.00; 1.20
Min; Max 0.80; 1.80 0.80; 1.80 0.80; 1.80 0.80; 1.80 0.90; 1.40 0.80; 1.80
Statistics U = 690.00; p = 0.754 U = 2740.50; p = 0.660 U = 161.50; p = 0.149
BDNF
Val66Met
Genotype A
carriers
(N = 32)
GG
carriers
(N = 42)
A
carriers
(N = 58)
GG
carriers
(N = 113)
A
carriers
(N = 15)
GG
carriers
(N = 43)
TG
(mmol/L)
Median 1.50 1.60 1.60 1.60 1.50 2.20
Percentile
25th; 75th
1.30; 1.80 1.20; 1.80 1.30; 2.20 1.20; 2.20 0.90; 2.20 1.50; 3.20
Min; Max 0.60; 2.70 0.60; 3.70 0.60; 3.70 0.60; 3.70 0.70; 3.70 0.70; 3.70
Statistics U = 639.50; p = 0.721 U = 3135.50; p = 0.790 U = 139.00; p = 0.042
BDNF
C270T
Genotype T
carriers
(N = 38)
CC
carriers
(N = 38)
T
carriers
(N = 52)
CC
carriers
(N = 110)
T
carriers
(N = 4)
CC
carriers
(N = 52)
HDL
(mmol/L)
Median 1.30 1.30 1.20 1.20 1.10 1.10
Percentile
25th; 75th
1.10; 1.50 1.10; 1.50 1.10; 1.50 1.10; 1.20 1.00; 1.45 1.00; 1.20
Min; Max 0.80; 1.80 0.80; 1.80 0.80; 1.80 0.80; 1.80 0.90; 1.80 0.80; 1.80
Statistics U = 723.00; p = 0.992 U = 2333.00; p = 0.054 U = 106.00; p = 0.963
BDNF
C270T
Genotype T
carriers
(N = 34)
CC
carriers
(N = 40)
T
carriers
(N = 56)
CC
carriers
(N = 115)
T
carriers
(N = 4)
CC
carriers
(N = 54)
TG
(mmol/L)
Median 1.55 1.50 1.55 1.60 1.55 2.20
Percentile
25th; 75th
1.30; 1.80 1.20; 1.80 1.20; 2.00 1.30; 2.30 1.35; 1.90 1.50; 2.70
Min; Max 0.80; 3.70 0.60; 3.40 0.60; 3.60 0.60; 3.70 1.20; 2.20 0.70; 3.70
Statistics U = 632.00; p = 0.463 U = 2945.50; p = 0.365 U = 66.50; p = 0.212
Results are presented as median and 25th (Q1) and 75th (Q3) percentiles after excluding outliers. A carriers (AA + AG) of the BDNF Val66Met (rs6265); GG (GG homozygous genotype)
carriers of the BDNF Val66Met; T carriers (TT + TC) of the BDNF C270T; CC carriers (CC homozygous genotype) of the BDNF C270T; BDNF, brain derived neurotrophic factor; HDL,
high density lipoprotein cholesterol; PTSD, posttraumatic stress disorder; TG, triglycerides.
significantly associated with metabolic indices in Caucasian
veterans with PTSD. Namely, BMI values, as well as plasma
total cholesterol, triglycerides, HDL and LDL cholesterol levels
did not differ significantly in veterans with PTSD subdivided
into carriers of the A allele (AA+AG) or the GG homozygous
genotype of BDNF Val66Met polymorphism. As there are no
such data in the literature, we might presume that this study
is the first to show no association of BDNF Val66Met variants
with BMI in combat veterans with PTSD. In line with our data,
BMI was not significantly different in A carriers compared to
GG genotype carriers of the BDNF Val66Met in elderly healthy
Chinese subjects (95), or in elderly healthy individuals who
were followed longitudinally (71). However, there are conflicting
results in the literature regarding this polymorphism and BMI
in control subjects. Opposing data were reported showing that
the A allele was associated with higher BMI in healthy adult
subjects (96), adult women (69), and in young preschool children
(70). On the other hand, there are also data showing that A
carriers were more frequently found in the group with lower
BMI in a large Korean epidemiological cohort (74), in a large
cohort of male Boston Puerto Rican subjects (67), adult healthy
Caucasian women (73, 75), healthy control male and female
subjects from the same population of Caucasian subjects of
Croatian origin (52, 72), or in children and adolescents (97). A
recent meta-analysis confirmed only one BDNF SNP, rs925946,
significantly related to obesity and BMI in large groups of healthy
subjects (98). Discrepancies in the results could be explained
by the different diagnostic groups (PTSD vs. controls), ethnic
background (19, 99, 100), age, gender, living environment, diet,
lifestyle, and smoking (95). Since recently a strong LD between
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BDNF rs6265 and rs10501087 was reported, suggesting that these
two SNPs are dependent genetic markers associated with BMI
(98), in future studies this BDNF SNP, rs10501087, should be also
evaluated.
Our study did not detect any significant association between
BDNF Val66Met and lipid levels in PTSD. There are no
findings in the literature regarding the association between BDNF
Val66Met and lipid levels in PTSD. However, in volunteers
without kidney and cardiovascular diseases, no association was
found between BDNF Val66Met polymorphism and serum TG
and HDL cholesterol levels (63). This finding agrees with the
results from our study, since our veterans with PTSD, who did
not have any cardiovascular or metabolic diseases, had similar
plasma lipid levels when subdivided into carriers of different
BDNF Val66Met variants. In children and adolescents from the
general population, the BDNF Val66Met polymorphism was not
associated with any of the lipid indices (97). In contrast to our
study and cited (63, 97) findings, the presence of one or two A
alleles of the BDNF Val66Met was significantly associated with
lower HDL cholesterol levels and higher risk for obesity in old
and very old Chinese healthy subjects (95). In that particular
study subjects carrying the A allele had elevated triglyceride
levels, but reduced HDL cholesterol levels compared to the GG
genotype carriers (95). The differences between studies are in
the diagnosis (PTSD vs. normal controls) and in the age of
included subjects (i.e., Peng’s study included three groups: age
≥90; age 60–77; and age 60–75, while our veterans were on
average 56 years old). To control for the effect of age, in our study
participants with PTSDwere subdivided into different age groups
(age range 38–51, 52–65, and 66–77 years), and their plasmaHDL
and triglyceride levels (that were significantly affected by age in
the hierarchical regression analysis) did not differ between BDNF
Val66Met A vs. GG genotype carriers and between BDNF C270T
T vs. CC genotype carriers. In addition, the observed differences
between studies might be due to ethnicity (Chinese vs. Caucasian
subjects), since there were significant ethnic related differences
in the frequency of the BDNF Val66Met genotypes, especially
the frequency of the AA genotype, between Asian and Caucasian
subjects (100).
Unlike BDNF Val66Met, the BDNF C270T polymorphism
has only recently gained attention in studies of neuropsychiatric
disorders (101). The T allele of the BDNF C270T polymorphism
was reported to be a risk factor for PTSD (46), schizophrenia (29),
bulimia nervosa (102), and amyotrophic lateral sclerosis (24), but
not for Alzheimer’s disease (78). The T allele prevalence in our
study was 17% and it was the same as the T allele frequency
in a Chinese sample with PTSD (46). This frequency differs
significantly from the T allele frequency in our healthy Caucasian
subjects (6%, unpublished data) and in the general East Asian
population [6%, (77)] or in other diagnostic groups. Namely, in
Caucasian patients with schizophrenia this frequency was around
8% (29), while in Caucasian patients with bulimia nervosa and
control subjects it was around 5% (102). Higher prevalence of
the T allele in our Caucasian subjects and in Chinese subjects
with PTSD (46) compared to control subjects (102) and patients
with schizophrenia (29) or bulimia (102), might be an outcome of
different clinical diagnoses (PTSD vs. schizophrenia vs. bulimia
nervosa/controls). This is also supported by the fact that no
obvious ethnic differences in BDNF C270T genotype frequency
were found in a recent meta-analysis (78) and reported by The
1000 Genomes Project Consortium (77), with the exception of
South Asian populations (India, Bangladesh, Pakistan) where the
T allele is present in 29% of population.
The BDNF C270T polymorphism was related to PTSD in one
study, since the T allele frequency was significantly higher in a
group with sporadic PTSD compared to a control group (46).
Another study did not find a significant association, but this trial
comprised only 96 subjects with PTSD (45). Since in our study we
have not compared the frequency of the BDNF C270T genotypes
in PTSD vs. controls, we cannot confirm or reject this finding.
This investigation has not found a significant association
between BDNF C270T and BMI, total cholesterol, LDL
cholesterol and triglyceride levels in veterans with PTSD. A
slight association between BDNF C270T and HDL cholesterol
in veterans with PTSD was detected, as carriers of the T alleles
had nominally higher HDL cholesterol levels than CC carriers.
This significance did not survive a Bonferroni correction, and
was not confirmed by hierarchical multiple regression and
further testing. Only HDL and triglyceride levels were affected
by age. Other metabolic indices were not associated with age,
smoking, BDNF Val66Met or BDNF C270T polymorphisms. To
further evaluate these findings, HDL and triglyceride levels were
evaluated in participants subdivided into 13-year age groups,
i.e., into individuals in the age range from 38 to 51, from 52
to 65, and from 66 to 77 years, although we are aware of
the limited power due to the stratification of data into smaller
groups. HDL and triglyceride levels did not differ between BDNF
Val66Met A allele carriers vs. GG genotype carriers, and between
BDNF C270T T allele carriers vs. CC genotype carriers. As both
BDNF C270T T allele carriers and CC genotype carriers showed
reduced median HDL values in older age, these results confirmed
that HDL was affected by age and not by the presence of the
T allele.
There are no other data on the association of this BDNF
C270T polymorphism and HDL cholesterol in PTSD, and there
are no data showing either a positive association or no association
between BDNF C270T polymorphism and BMI, total cholesterol,
LDL cholesterol and triglyceride levels in PTSD. Although this
was the first study to evaluate a link between BDNF C270T and
metabolic indices in PTSD, no associations were found between
either of the variants and these metabolic indices. One study
reported that BDNF C270T polymorphism was not associated
with BMI in patients with anorexia nervosa and bulimia nervosa
(103), while another found a significant association between the
T allele of the BDNF C270T polymorphism and lower BMI in
bulimia nervosa (102). The discrepancies between these and our
study might be explained by the differences in diagnoses (PTSD
vs. eating disorders).
Our results did not confirm our hypothesis that BDNF
Val66Met and C270T variants contribute to susceptibility to
metabolic disturbances in PTSD. Lower HDL cholesterol values
were detected in older individuals with PTSD, but were not
associated with any of the BDNF Val66Met and C270T genotypes.
Routine monitoring of individuals with PTSD, in terms of HDL
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cholesterol levels, might prevent possible cardiovascular events
including myocardial infarction, that are frequent in PTSD (5,
17, 84).
Some limitations need to be considered in interpreting these
results: the study included only Caucasian PTSD veterans, and
all participants were males. Therefore, we could not compare our
data with those in control subjects, and we could not evaluate
possible ethnic and gender related differences. In this study
we included only the two SNPs (BDNF Val66Met and C270T
polymorphisms), so additional BDNF gene polymorphisms
should be included in future studies, such as those evaluated
in healthy control subjects: BDNF rs12291063 polymorphism
associated with BMI and obesity (104), BDNF rs10767664
polymorphism associated with BMI, weight, fat mass, waist
circumference, LDL cholesterol and total cholesterol (105), or
BDNF rs925946 polymorphism associated with BMI (98), or
GWAS data. Data on physical activity and eating habits were
not collected. A significant limitation of this study is a lack of
replication sample.
Advantages of the present study are the use of a fairly large
group of veterans with PTSD, sampled from the same center, and
in the fact that diagnosis and screening for PTSD was done by
psychiatrists using SCID and CAPS. We also took into account
alcohol dependence and use of statins and cardiovascular drugs,
we removed outliers, carefully monitored the confounders by
a hierarchical multiple linear regression, used a homogeneous
group of Caucasians of Croatian origin with similar combat
trauma exposure and ensured that the study had the required
sample size and statistical power.
CONCLUSION
This is a first report showing that variants of the BDNF Val66Met
and BDNF C270T polymorphisms were not associated with BMI
or plasma lipid levels in veterans with PTSD.Our findings suggest
that BDNF Val66Met and C270T variants do not contribute
to susceptibility to metabolic disturbances in PTSD. Other
metabolic indices and other BDNF and other gene variants
should be evaluated as metabolic risk factors in PTSD in further
larger multi-ethnic studies, including females, larger sample-
sizes, with well-matched controls.
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